WASHINGTON, May 1 -- Food and Drug Administration has issued a notice called: Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments.
The notice was published in the Federal Register on May 1 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.
Summary: The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect examples about how previous patient-focused drug development (PFDD) meetings have impacted stakeholders' drug development efforts. This includes impacts on community engagement, research priorities, advocacy strategies, medical product development programs, clinical practice, and oth...